Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02269 WUXI BIO
RTNominal up14.300 +0.540 (+3.924%)
Research Report

19/02/2020 11:49

{I-bank focus}BofA raises WuXi Biologics (02269) to HK$129

[ET Net News Agency, 19 February 2020] BofA Global Research upped its target price for
WuXi Biologics (02269) to HK$129 from HK$117 and maintained its "buy" rating.
In addition to Gloria's PD-1 GLS-010 and Amicus' ATB200 for which WuXi Bio would be
a commercial manufacturer, the research house thinks WuXi is also manufacturing clinical
trial material for GSK's PD-1 TSR042, CStone's PD-L1 CS1001, Acrus' PD-1 AB122, Momenta's
FcRn antibody M281 and Eylea biosimilar M710, Immutep's LAG-3 antibody IMP321, InflaRx's
IFX-1.
BofA believes WuXi Bio could become a commercial manufacturer for those drugs' as
well. In particular, there could be catalysts in addition to the WuXi Vaccine contract
signing: IMP321 Ph2 combo data in 1L NSCLC on 19 February and Ph2 combo data in mBC in
1Q 2020, M281 Ph2 data in generalized myasthenia gravis in 3Q 2020, CS1001 NDA filing in
China, and WuXi's 2019-nCoV neutralizing antibody development achievements. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.